Multiple mitochondrial components generate reactive oxygen species (ROS), but separating the consequences of each ROS-generating source from overall mitochondrial health is challenging. A new class of small-molecule inhibitors that selectively block ROS generation from one of the most active sources may provide a new approach toward achieving that goal.
